HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IVA
Inventiva S.A.
There isn't enough reported data to score IVA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IVA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
IVA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IVA PE Valuation
IVA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IVA Forward outlook
There aren't enough analyst estimates for IVA to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2025 | -$4.18 | -$1.89 |
| Q4 2024 | -$3.42 | -$0.72 |
IVA and HIMS do not have enough comparable growth data to identify a winner.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over IVA on profitability, with a higher operating margin.
IVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1.4M | -71% |
| Q4 2025 | $32K | -100% |
| Q2 2025 | $4.9M | +10763% |
| Q4 2024 | $10.2M | -41% |
| Q2 2024 | $45.5K | -98% |
| Q4 2023 | $17.3M | +1% |
| Q2 2023 | $2.1M | +2737% |
| Q4 2022 | $17.1M | +280% |
IVA has the edge over HIMS in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -5394% | +122043 points |
| Q4 2025 | -257580% | -257274 points |
| Q2 2025 | -1413% | +1480 points |
| Q4 2024 | -495% | -342 points |
| Q2 2024 | -127437% | -72928 points |
| Q4 2023 | -306% | +451 points |
| Q2 2023 | -2893% | +18128 points |
| Q4 2022 | -153% | +7295 points |
IVA's operating margin was −5394% last quarter, up 122043 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
IVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2022 | -$21.1M | +$10.3M |
| Q2 2022 | -$29.5M | -$16M |
| Q4 2021 | -$31.3M | -$5M |
| Q2 2021 | -$13.5M | -$9.5M |
| Q4 2020 | -$26.3M | -$15.5M |
| Q2 2020 | -$4M | +$16.9M |
| Q4 2019 | -$10.8M | +$10.4M |
| Q2 2019 | -$20.9M | -$3.6M |
IVA has burned cash in almost every quarter: −$177M over the past year, against −$75M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IVA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +109% | +56.9M shares |
| 1 year | +159% | +66.8M shares |
| 3 years | +390% | +86.6M shares |
| 5 years | +985% | +98.8M shares |
IVA has 109M diluted shares, up 159% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $56.6M |
| Q4 2025 | — |
| Q4 2022 | — |
| Q2 2022 | — |
| Q4 2021 | — |
| Q2 2021 | — |
| Q4 2020 | — |
| Q2 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IVA Net Leverage
IVA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.5 | Neutral |
| Stochastic | 42.0 | Neutral |
IVA's weekly RSI is 47 (neutral) and its Stochastic is 42 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IVA PE vs Healthcare Sector
IVA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.51 | 11% above |
| 20 week MA | $4.06 | 4.4% below |
| 50 week MA | $4.78 | 19% below |
| 100 week MA | $4.22 | 8.1% below |
| 200 week MA | $3.89 | 0.3% below |
IVA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.4 | $12.8 | -4.6% |
| 2021 | $12.8 | $13.7 | +7.1% |
| 2022 | $13.7 | $4.45 | -68% |
| 2023 | $4.45 | $4.52 | +1.6% |
| 2024 | $4.52 | $2.20 | -51% |
| 2025 | $2.20 | $4.48 | +104% |
| 2026 YTD | $4.48 | $3.88 | -13% |
IVA has the edge over HIMS on returns for 2026, with the stronger performance.